Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$60.77
+1.4%		$46.76
$25.36
▼
$61.70
$2.99B1.261.40 million shs1.30 million shs
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$9.41
+2.3%		$8.11
$1.87
▼
$10.05
$2.64B2.085.04 million shs5.29 million shs
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
$4.27
$4.27
$0.78
▼
$4.40
$891.09MN/A1.99 million shsN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$83.90
-3.6%		$84.46
$60.10
▼
$156.00
$3.04B1.9709,980 shs623,666 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.35%+2.79%+24.84%+101.36%+68.38%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
+1.94%+18.30%+3.93%+6.89%+353.54%
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
0.00%0.00%0.00%0.00%0.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-3.56%-3.18%-10.36%+22.59%-28.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$60.77
+1.4%		$46.76
$25.36
▼
$61.70
$2.99B1.261.40 million shs1.30 million shs
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$9.41
+2.3%		$8.11
$1.87
▼
$10.05
$2.64B2.085.04 million shs5.29 million shs
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
$4.27
$4.27
$0.78
▼
$4.40
$891.09MN/A1.99 million shsN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$83.90
-3.6%		$84.46
$60.10
▼
$156.00
$3.04B1.9709,980 shs623,666 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.35%+2.79%+24.84%+101.36%+68.38%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
+1.94%+18.30%+3.93%+6.89%+353.54%
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
0.00%0.00%0.00%0.00%0.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-3.56%-3.18%-10.36%+22.59%-28.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
2.75
Moderate Buy$53.30-12.29% Downside
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
2.50
Moderate Buy$7.25-22.96% Downside
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
0.00
N/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.33
Hold$121.1044.34% Upside

Current Analyst Ratings Breakdown

Latest CVRS, TMDX, ATRC, and BFLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
9/22/2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
9/17/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$65.00
9/11/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/11/2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
9/8/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/2/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $64.00
8/31/2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/27/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$50.00 ➝ $60.00
8/24/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/24/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $55.00
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$534.53M5.78$0.32 per share187.96$9.89 per share6.14
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$97.61M25.67N/AN/A$0.77 per share12.22
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/AN/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$605.49M4.79$3.74 per share22.43$13.79 per share6.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$11.45M$0.21289.39135.04N/A1.85%2.34%1.77%11/4/2026 (Estimated)
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$77.06M-$0.29N/AN/AN/A-66.74%-33.99%-22.96%10/30/2026 (Estimated)
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$190.29M$3.8921.5737.121.2122.69%15.88%5.95%11/4/2026 (Estimated)

Latest CVRS, TMDX, ATRC, and BFLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.4955$0.44-$0.0555$0.41$184.00 million$189.95 million
7/30/2026Q2 2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$0.0350-$0.01+$0.0250-$0.05$29.16 million$32.61 million
7/23/2026Q2 2026
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.0017$0.18+$0.1817$0.18$151.80 million$153.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/AN/AN/AN/AN/A
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.14
4.22
3.19
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/A
4.06
3.06
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.62
6.62
6.07

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
37.85%
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
4.00%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
21.99%
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,35050.87 million48.83 millionOptionable
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
220266.29 million207.73 millionOptionable
Corindus Vascular Robotics Inc stock logo
CVRS
Corindus Vascular Robotics
90208.69 millionN/ANot Optionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
89834.56 million32.18 millionOptionable

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)
September 23 at 7:58 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TMDX/pressreleases/4750087/analysts-offer-insights-on-healthcare-companies-dbv-technologies-sa-american-dbvt-and-transmedics-group-tmdx/
【TMDX】TransMedics Group
September 19, 2026  |  note.comN
TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947750-transmedics-waiting-on-2027-catalysts
TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% on Insider Buying Activity
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027707
David Weill Acquires 1,336 Shares of TransMedics Group (NASDAQ:TMDX) Stock
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027340
TransMedics Group, Inc. (TMDX) Presents at 2026 Global Healthcare Conference - Slideshow
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946659-transmedics-group-inc-tmdx-presents-at-2026-global-healthcare-conference-slideshow
TransMedics Group (NASDAQ:TMDX) Trading Up 4.5% on Insider Buying Activity
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-transmedics-group-nasdaq-tmdx-trading-up-45-on-insider-buying-activity-2026-09-15/
2 Stocks Down 28% and 34% to Buy and Hold
September 15, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/15/2-stocks-down-28-and-34-that-to-buy-and-hold/
Insider Buying: TransMedics Group (NASDAQ:TMDX) Director Purchases $109,057.68 in Stock
September 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tmdx-insider-buying-and-selling-2026-09-15/
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946220-transmedics-group-inc-tmdx-presents-at-morgan-stanley-24th-annual-global-healthcare
Insider Buying: TransMedics Group (NASDAQ:TMDX) Director Buys 1,336 Shares of Stock
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-buying-transmedics-group-nasdaq-tmdx-director-buys-1336-shares-of-stock-2026-09-14/
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
September 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260914420394/en/transmedics-group-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-transmedics-group-inc.---tmdx/
Canaccord Genuity Keeps Their Buy Rating on TransMedics Group (TMDX)
September 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4572061/canaccord-genuity-keeps-their-buy-rating-on-transmedics-group-tmdx/
TransMedics Group Names New Chief Financial Officer
September 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TMDX/pressreleases/4565249/transmedics-group-names-new-chief-financial-officer/
TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.1% - What's Next?
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-transmedics-group-nasdaq-tmdx-stock-price-down-41-whats-next-2026-09-11/
TransMedics Group, Inc.: TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
September 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69552894-transmedics-group-inc-transmedics-appoints-fernando-araujo-as-chief-financial-officer-and-reiterates-2026-financial-outlook-008.htm
Transmedics Names Fernando Araujo CFO, Reiterates FY26 Outlook
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690146/transmedics-names-fernando-araujo-cfo-reiterates-fy26-outlook.aspx
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
September 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/transmedics-appoints-fernando-araujo-as-chief-financial-officer-and-reiterates-2026-financial-outlook-302875738.html
TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Hold" by Brokerages
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-transmedics-group-inc-nasdaq-tmdx-given-consensus-rating-of-hold-by-brokerages-2026-09-10/
TransMedics Group's (TMDX) "Buy" Rating Reiterated at TD Cowen
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-transmedics-groups-tmdx-buy-rating-reiterated-at-td-cowen-2026-09-08/
TransMedics: Slowing Growth Brings Its Valuation Into Question
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943749-transmedics-slowing-growth-brings-its-valuation-into-question

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$60.77 +0.81 (+1.35%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$61.42 +0.65 (+1.07%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Butterfly Network stock logo

Butterfly Network NYSE:BFLY

$9.41 +0.21 (+2.29%)
Closing price 09/24/2026 03:59 PM Eastern
Extended Trading
$9.34 -0.07 (-0.78%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Corindus Vascular Robotics stock logo

Corindus Vascular Robotics NYSEAMERICAN:CVRS

$4.27 0.00 (0.00%)
As of 11/27/2019

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$83.90 -3.10 (-3.56%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$83.06 -0.84 (-1.01%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas